Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L)

BACKGROUND: Bevacizumab, a humanized antibody to vascular endothelial growth factor (VEGF), shows clinical activity against human cancer, with its addition to standard chemotherapy having been found to improve outcome in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). However,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Takeda, Masayuki, Okamoto, Isamu, Yamanaka, Takeharu, Nakagawa, Kazuhiko, Nakanishi, Yoichi
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2012
Matèries:
Study Protocol
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3500214/
https://ncbi.nlm.nih.gov/pubmed/22849580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-12-327
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars